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Abstract: Medication adherence among patients with chronic diseases, such as COPD, may 
be suboptimal, and many factors contribute to this poor adherence. One major factor is the 
frequency of medication dosing. Once-daily dosing has been shown to be an important variable 
in medication adherence in chronic diseases, such as COPD. New inhalers that only require 
once-daily dosing are becoming more widely available. Combination once-daily inhalers that 
combine any two of the following three agents are now available: 1) a long-acting muscarinic 
antagonist; 2) a long acting beta
2
 agonist; and 3) an inhaled corticosteroid. A new once-daily 
inhaler with both a long-acting muscarinic antagonist, umeclidinium bromide, and a long act-
ing beta
2
 agonist, vilanterol trifenatate, is now available worldwide for COPD treatment. It 
provides COPD patients convenience, efficacy, and a very favorable adverse-effects profile. 
Additional once-daily combination inhalers are available or will soon be available for COPD 
patients worldwide. The use of once-daily combination inhalers will likely become the standard 
maintenance management approach in the treatment of COPD because they improve medica-
tion adherence.
Keywords: medication adherence, long-acting beta
2 
agonist, long-acting muscarinic antagonist, 
inhaled corticosteroid, chronic obstructive pulmonary disease
Introduction
COPD is a syndrome that is a major and steadily increasing cause of chronic morbid-
ity and mortality worldwide.1 In a recent, large, Western European epidemiological 
study, the incidence rate of physician-diagnosed COPD was 2.92/1,000 persons–years 
and the prevalence was 3.02% (95% confidence interval [CI], 2.94%–3.10%).1 The 
prevalence of COPD increases with age; it has been climbing globally since 1990 
and is expected to continue to do so through 2020 as the population of current and 
former smokers ages.2 COPD is underdiagnosed both in its early stages and when it 
is more advanced.2 Reducing further lung exposure to cigarette smoke, which is the 
single most important causal factor in the development of COPD, will help reduce 
this substantial disease burden. However, not all COPD is related to smoking; other 
risk factors for the disease include genetic factors and other environmental and occu-
pational exposures.3
Because of the huge health burden that COPD represents, new medications continue 
to be developed to treat the symptoms of COPD. This review will focus on adher-
ence to the use of these medications with a particular focus on the once-a-day dry 
powder fixed-dose combination of umeclidinium bromide, a long-acting muscarinic 
Correspondence: Timothy e Albertson
Department of internal Medicine, 
4150 v Street, Suite 3100, Sacramento, 
CA 95817
email tealbertson@ucdavis.edu 
Journal name: Patient Preference and Adherence
Article Designation: Review
Year: 2015
Volume: 9
Running head verso: Albertson et al
Running head recto: Umeclidinium/vilanterol inhaler for COPD
DOI: http://dx.doi.org/10.2147/PPA.S71535
Patient Preference and Adherence 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
236
Albertson et al
antagonist (LAMA), and vilanterol trifenatate, a long-acting 
beta
2
 agonist (LABA), for the treatment of COPD.
Effect of dosing frequency 
on medication adherence 
in chronic disease
The adherence to medication use in chronic disease is influ-
enced by a number of factors. Individual factors such as 
socioeconomic status, age, sex, race, and mental status and 
health system factors such as health literacy, convenience of 
pharmacy, and the complexity of the medication regimens all 
contribute to medication adherence by chronically diseased 
patients.4,5 Looking at patients with geriatric depression, 
human immunodeficiency virus, diabetes mellitus, and 
hypertension, Libby et al used the Medication Regimen 
Complexity Index to evaluate medication adherence. They 
found that dosing frequency and the variety of dosage forms 
were important components of medication complexity.4 
They recommended reducing complexity, such as decreas-
ing dosing frequencies, for all chronic disease management 
programs.
The association of better dosing adherence with less fre-
quent dosing has been reported in systematic reviews and meta-
analyses performed for chronic psychiatric disease,6 for chronic 
cardiovascular disease,7,8 and for venous thromboembolism.9 
In a large, systematic review of dosing frequency and medica-
tion adherence in chronic disease, Coleman et al reported that 
the percentage values of adjusted weighted-mean–adherence 
rates compared to those for once-a-day dosing were 6.7% 
lower for two times-a-day, 13.5% lower for three times-a-
day, and 19.2% lower for four times-a-day dosing regimens.10 
Timing adherence was even worse; compared to the rate for 
once-a-day dosing, the rates were 26.7% lower for twice-a-
day dosing, 39.0% lower for three-times-a-day dosing, and 
54.2% lower for four-times-a-day dosing.10 Another systematic 
review of dosing-frequency adherence in chronic diseases 
found that patients were statistically (P0.05) more compli-
ant with once-a-day dosing regimens than with twice-daily 
or thrice-daily dosing regimens.11 Dosing frequency clearly 
plays an important role in predicting medication adherence 
in chronic disease, and once-daily dosing regimens show the 
best adherence.
Medication adherence in COPD
Medication adherence in patients with COPD, like with all 
chronic diseases, is a complex issue, but adherence is crucial 
for the best outcomes. The addition of inhaled medications 
to an oral regimen further adds to this complexity. In a study 
of 575 Medicare beneficiaries in California, 70% reported 
taking medications “all of the time”. Forgetfulness, side 
effects, difficulty paying for medications, complicated 
administration instructions, complicated drug names, and 
English as a second language were all identified as adherence 
barriers.5 In COPD, poor inhaler technique has been associ-
ated with inadequate training and poor outcomes.12,13 
Poor health-related quality of life (HRQOL) has also 
been associated with poor medication adherence in COPD. 
Other studies have suggested that an improved HRQOL in 
COPD can also trigger medication nonadherence.14,15 This 
dual relationship between medication adherence and HRQOL 
suggests that the dynamics between the two can differ over 
time. In another study, no association between medication 
compliance and demographic variables was reported for 
COPD, but adherence was related to the classes of medication 
(eg, patients on steroids and antibiotics adhered more to their 
medication prescriptions than did those using theophylline 
or inhalers) and situational variables (eg, forgetting a dose 
related to feeling good, a change in routine, or the incon-
venience of dosing).16 There are limited amounts of data to 
support the roles that reduced out-of-pocket expenses, the use 
of case management, and patient education have in improving 
long-term medication adherence and health outcomes in a 
variety of disease states, as discussed in a recent systematic 
review.17 In other studies, patient satisfaction with the inhaler, 
knowledge and education about the inhaler, inhaler conve-
nience, and medication costs have been shown to be factors 
in medication adherence in COPD.18,19 This benefit is often 
enhanced with the addition of pulmonary rehabilitation and 
group education programs.17 Electronic medication delivery 
devices that give the COPD patient feedback and disease and 
medication education by pharmacists and the primary care 
team are advocated as ways to improve medication adherence 
in COPD, but again, the amount of quality data to support 
the recommendations is limited.20–22 
In a retrospective study using a large administrative 
claims database and controlling for demographics, comorbid-
ities, and baseline resources, medication adherence in 55,076 
COPD patients strongly correlated with dosing frequency.23 
Adherence measured as the proportion of days in which 
prescribed drugs were used over 12 months was 43.7% for 
once-a-day, 37.0% for twice-a-day, 30.2% for three times-a-
day, and 23.0% for four times-a-day dosing. Through the use 
of an administrative database of COPD patients and after con-
trolling for potentially confounding factors, it was found that 
multiple-inhaler users experienced more exacerbations and 
had higher health care costs than did single-inhaler users.24 
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Combination-product inhalers have been advocated to 
improve medication adherence in the treatment of COPD 
for some time.25 Several studies have suggested better adher-
ence and outcomes when COPD patients use combination 
inhalers over single-product inhalers.26–28 These studies are 
often confounded by comparing a combination steroid/
bronchodilator inhaler to a single bronchodilator inhaler. In 
a systematic review of ten articles on medication adherence 
in COPD from 2008–2009, Charles found that the twice-a-
day combination inhaler fluticasone propionate/salmeterol 
xinafoate combined with the once-a-day inhaler tiotropium 
was associated with the highest adherence among all con-
troller medications available at that time.21 Together, these 
data suggest that medication adherence by COPD patients 
is poor and that the reasons are multifactorial. Inhalers that 
use combinations of medications in conjunction with once-
a-day dosing frequencies can improve medication adherence 
in these patients. Table 1 is a summary of current inhalers 
that are dosed once-a-day, and Table 2 offers the current 
combination drug inhalers that are available and approved 
by the US Food and Drug Administration (FDA).
Once-a-day, long-acting inhalers 
in COPD
The healthcare costs for patients with COPD increased by 
38% between 1987 and 2007 in the USA and continued to 
increase by approximately 5% annually between 2006 and 
2009.29 The major driver for this increase was the cost of 
acute exacerbations of COPD; annual healthcare costs are 
tenfold greater for COPD patients with exacerbations than 
for those without. The use of LABAs, LAMAs, and ICSs as 
maintenance therapy remain underutilized; only 30%–35% 
of COPD patients receive prescriptions for maintenance 
therapy.29
In a systematic review, the use of twice-daily LABAs by 
patients with moderate-to-severe COPD was more effective 
over the medium term and long term than was the use of the 
placebo. Their use was associated with improved quality 
of life and reduced COPD exacerbations.30 New once-daily 
LABA inhalers that have been approved by the FDA for use 
in COPD include olodaterol, delivered by the spring-driven 
mist (SDM) device Respimat®, and indacaterol, delivered 
as a dry powder.31–34 In a systematic review of randomized, 
controlled clinical trials in patients with COPD, a similar 
efficacy with olodaterol and indacaterol was reported.35 
The use of the inhaled LAMA tiotropium and the use of a 
placebo was compared in a systematic review. In the review, 
inhaled tiotropium treatment once-a-day was associated 
with significant improvement in the patient’s quality of life 
and resulted in a reduction in the risk of exacerbations.36 In 
another review of tiotropium bromide inhalation for COPD, 
it was also concluded that the once-daily LAMA was asso-
ciated with improved lung function, dyspnea, and HRQOL 
scores, and was associated with the reduced incidence of 
acute COPD exacerbations.37 By using claims data, inhaled 
tiotropium was found to be associated with a higher adher-
ence than was twice-daily inhaled fluticasone/salmeterol 
among COPD patients. Medication adherence in this study 
was associated with lower respiratory-related medical and 
inpatient costs.38 Another retrospective study in the USA 
reported fewer COPD exacerbations, hospitalizations, and 
hospital days among patients receiving tiotropium. This 
resulted in a reduction of total healthcare costs of greater than 
$1,000 per patient in the tiotropium-treated group.39 
The dry powder, once-daily combination inhaler with the 
LABA vilanterol and the ICS fluticasone furoate has been 
approved by the FDA for the treatment of COPD. Significant 
improvement in lung function was demonstrated in moderate-
to-severe COPD patients using that therapy.40–42 In addition, 
once-daily inhalation of fluticasone furoate and vilanterol was 
associated with a decrease in moderate and severe COPD 
exacerbations in patients with a history of exacerbations. 
This reduction in exacerbations was also associated with a 
small increase in the risk of pneumonia.43
Table 1 Once a day inhalers used in COPD
Drug(s) Dose per inhalation Drug type Inhaler type Brand name
Umeclidinium bromide + vilanterol trifenatate 0.0625 mg +0.025 mg LAMA + LABA Dry powder Anoro ellipta®,C
Fluticasone furoate + vilanterol trifenatate 0.1 mg +0.025 mg iCS + LABA Dry powder Breo ellipta®,C
indacaterol maleate 0.075 mg LABA Dry powder Arcapta Neohaler®,C
Olodaterol hydrochloride 0.0025 mgD LABA SDM Striverdi Respimat®,C
Tiotropium bromide 0.018 mg LAMA Dry powder Spiriva Handihaler®,C
Tiotropium bromide 0.0025 mgD LAMA SDM Spiriva Respimat®,C
Notes: Cindicates an FDA approved indication for COPD; Dindicates two inhalations of 0.0025 mg once daily.
Abbreviations: LAMA, long-acting muscarinic antagonist; LABA, long-acting beta2 adrenergic agonist; iCS, inhaled corticosteroid; SDM, spring-driven mist inhaler; 
FDA, US Food and Drug Administration. 
Patient Preference and Adherence 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
238
Albertson et al
Umeclidinium bromide is a new quinuclidine-based qua-
ternary ammonium LAMA not yet FDA approved for use in 
COPD as a single agent. In a double-blind, placebo-controlled 
trial, once-daily inhalation of a dry powder of umeclidinium 
was compared to twice-daily doses and to once-daily tiotro-
pium inhalation. Once-daily inhaled umeclidinium was 
associated with increases in lung function comparable to 
those seen with twice-daily dosing and with once-daily tiotro-
pium, and all three were superior to the placebo.44 Similar 
sustained improvement in lung function and a reduced need 
for short-acting beta
2
 agonists (SABAs) have been reported 
with once-daily inhaled umeclidinium.45,46
The first long-acting combination inhaled bronchodilator 
was the LABA indacaterol paired with the LAMA glycopyr-
ronium. It is approved in Japan, Europe, and Great Britain 
for maintenance therapy in COPD, but this combination has 
not been approved in the USA. In patients with moderate-to- 
severe COPD, once-daily inhaled indacaterol/glycopyrronium 
was associated with better improvement in forced expiratory 
volume 1-second (FEV
1
) at week 12 than was a combination 
of indacaterol and a placebo.47 The combination once-daily 
inhaler glycopyrronium/indacaterol was studied for 26 weeks 
in 2,144 moderate-to-severe COPD patients in the SHINE 
study.48 The study researchers found greater improvement 
in trough FEV
1
, dyspnea scores, and health status scores 
with this inhaler than with the inhaled placebo, indacaterol 
alone, glycopyrronium alone, or tiotropium alone.48 In an 
analysis of a combination of five clinical trials (41,842 COPD 
patients), glycopyrronium alone, tiotropium alone, and a 
glycopyrronium/indacaterol combination were compared in 
a systematic review.49 The once-daily combination inhaler 
was found to be associated with better trough FEV
1
 (70 mL, 
P0.0001) and less frequent use of rescue SABA inhalers 
(-0.63 puffs/day, P0.0001) than was the once-daily LAMA 
tiotropium alone. The efficacy of glycopyrronium/indacaterol 
was shown to be superior to glycopyrronium inhaled alone 
in patients with moderate-to-severe COPD.49
In a study in Sweden, researchers evaluated the cost-
effectiveness of indacaterol/glycopyrronium as a once-
daily fixed-dose combination therapy in COPD patients 
and compared it to that of an indacaterol inhaler plus a 
glycopyrronium inhaler and to the fixed twice-daily inhaler 
salmeterol/fluticasone; they used data from the SHINE study 
and a cost-minimization analysis in which equal efficacy was 
assumed. After including direct and indirect drug acquisi-
tion costs in Sweden, the combination inhaler indacaterol/
glycopyrronium was significantly cheaper than indacaterol 
inhaler plus glycopyrronium inhaler or the combined 
salmeterol/fluticasone inhaler.50 Local indirect and direct 
drug costs can change these calculations, but in general 
combination inhalers are less expensive than the component 
drugs as individual inhalers.
The once-daily combination inhaler 
umeclidinium bromide/vilanterol 
trifenatate in the treatment of COPD
Currently, there are three fixed-dose combination long-acting 
once-daily inhalers approved in Europe and Japan for the 
Table 2 Combination inhaled drugs for airway diseases
Drug combination Dose per inhalation Drug type Frequency Inhaler type Brand name
Umeclidinium bromide  
+ vilanterol trifenatate
0.0625 mg +0.025 mg LAMA + LABA qd Dry powder Anoro ellipta®,C
Fluticasone furoate +  
vilanterol trifenatate
0.1 mg +0.025 mg iCS + LABA qd Dry powder Breo ellipta®,C
Budesonide + Formoterol  
fumarate
0.08 mg +0.0045 mg 
or 0.16 mg +0.0045 mg
iCS + LABA bid MDi Symbicort®,A,C
Fluticasone propionate  
+ salmeterol xinafoate
0.1 mg +0.05 mg; 0.25 mg +0.05 mg;
or 0.5 mg +0.05 mg
iCS + LABA bid Dry powder Advair Diskus®,A,C
Fluticasone propionate  
+ salmeterol xinafoate
0.045 mg +0.021 mg; 0.115 mg +0.021 mg; 
or 0.230 mg +0.021 mg
iCS + LABA bid MDi Advair HFA®,A
Mometasone furoate  
+ formoterol fumarate
0.1 mg +0.005 mg or 0.2 mg +0.005 mg iCS + LABA bid MDi Dulera®,A
Albuterol sulfate +  
ipratropium bromide
2.5 mg +0.5 mg SABA + SAMA qid Neb DuoNeb®,C + genericsC
Albuterol sulfate +  
ipratropium bromide
0.1 mg +0.03 mg SABA + SAMA qid SDM Combivent Respimat®,C
Notes: Cindicates an FDA approved indication for COPD; Aindicates an FDA approved indication for asthma.
Abbreviations: LAMA, long-acting muscarinic antagonist; LABA, long-acting beta2 agonist; iCS, inhaled corticosteroid; SABA, short-acting beta2 agonist; SAMA, short-acting 
muscarinic antagonist; qd, once-a-day; bid, twice-a-day; qid, four times-a-day; MDi, metered dose inhaler; Neb, nebulized drug; SDM, spring-driven mist; FDA, US Food and 
Drug Administration.
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chronic treatment of COPD: the LAMA/LABA combination 
glycopyrronium/indacaterol, the ICS/LABA combination 
fluticasone/vilanterol, and the LAMA/LABA combina-
tion umeclidinium/vilanterol.51 Two of these agents, fluticasone/ 
vilanterol and umeclidinium/vilanterol, are currently FDA 
approved in the USA for treatment of COPD. The LAMA 
umeclidinium (62.5 µg) combined with the LABA vilanterol 
(25 µg) is approved for once-daily maintenance therapy of 
COPD in the USA.52 When the umeclidinium/vilanterol 
(UMEC/VI) combined once-daily inhaler was compared to 
either an inhaler of umeclidinium alone, vilanterol alone, 
or placebo in 1,493 COPD patients over 24 weeks, greater 
improvements in lung function, health status, and dyspnea 
were seen with UMEC/VI than with the monotherapies or 
the placebo.53 When the UMEC/VI inhaler was compared 
to the placebo inhaler, the hazard ratio for COPD exacerba-
tion was 0.4 (95% CI, 0.2–0.6, P 0.001), and rescue SABA 
albuterol (SABA) use decreased by 0.7 puffs/day for placebo 
and decreased by 2.2 puffs/day for UMEC/VI (difference 
of -1.7 puffs/day, P0.001) from week 1 to week 24.53 In a 
double-blind, multicentered, double-dummy, parallel-group 
trial in 2,332 COPD patients treated for 24 weeks with high-
dose (125 µg) UMEC/VI, low-dose (62.5 µg) UMEC/VI, VI 
(27 µg) alone, tiotropium alone, or high-dose UMEC alone, 
both doses of UMEC combined with VI were associated with 
better trough FEV
1
 than was VI monotherapy. An improve-
ment of 0.088 L (0.036–1.4 L, P=0.001) was seen for the 
125 µg (high-dose) UMEC/VI regimen and 0.09 L improve-
ment (0.039–0.142 L, P=0.0006) was seen for the 62.5 µg 
(low-dose) UMEC/VI regimen compared to VI alone.54 No 
significant differences in symptoms, health status, or risk 
of exacerbation were seen between either of the two doses 
of combination UMEC/VI inhaler and either the tiotropium 
inhaler or the high-dose UMEC inhaler alone. For both doses 
of the UMEC/VI inhaler, trough FEV
1
 values on day 169 were 
better than on day 1, and the improvement was more than was 
seen with the tiotropium inhaler alone. The difference between 
tiotropium and 125 µg (high-dose) UMEC/VI was 0.088 L 
(95% CI, 0.036–0.140, P=0.001); the difference between tiotro-
pium and 62.5 µg (low-dose) UMEC/VI was 0.09 L (95% CI, 
0.039–0.141 L, P=0.006).54 The low dose UMEC (62.5 µg)/IV 
(25 µg) is the approved formulation in the USA. In a 24-week, 
double-blind, placebo-controlled trial of 1,532 COPD patients 
randomized to either UMEC (62.5 µg)/VI (25 µg), UMEC 
(62.5 µg) alone, VI (25 µg) alone, or placebo once-daily 
inhalers, lung-function indicators including trough FEV
1
, 
symptoms, and HRQOL were assessed. All active treatments 
were associated with significantly greater trough FEV
1
 than 
was the placebo (0.072–0.167 L, all P0.001), and both 
combination UMEC/VI inhalers were significantly better than 
either monotherapy (0.052–0.095 L, P0.004).55 Reduced 
use of the SABA albuterol rescue inhaler, better symptom 
scores, and improved HRQOL endpoints were also seen in a 
comparison of UMEC/VI with the placebo. 
In safety and tolerability studies of high-dose UMEC 
(125–500 µg)/VI (25 µg) inhalers for COPD, patients who used 
the inhalers showed no differences in pulse rates, blood pressure, 
or corrected QT (QTc) intervals from the patients who took 
the placebo.56,57 Over a 52 week trial, the incidence of ectopic 
supraventricular beats, sustained supraventricular tachycardia, and 
ectopic supraventricular rhythm were 2% with the high-dose 
(125 µg) UMEC/VI inhaler than with the placebo inhaler.57
There are no apparent pharmacokinetic interactions 
between umeclidinium and vilanterol when coadministered 
in patients with COPD.58 When umeclidinium (500 µg) was 
combined with vilanterol (50 µg) by inhalation in healthy 
Japanese subjects, it was well tolerated. Both drugs showed 
rapid absorption with maximum serum concentrations within 
5 minutes and with rapid elimination terminal half-lives of 
0.42 hours for vilanterol and 0.71 hours for umeclidinium.59 
The maximal plasma concentration of umeclidinium was 
995.9 pg/mL (776.0–1,278.1 pg/mL) and was 1,299.0 pg/mL 
(1,026.0–1,644.7 pg/mL) for vilanterol. The average heart 
rate increase was 4.8 (0.6–9.1) beats/minute.59 In a large 
study of patients with COPD treated with fixed-dose umecli-
dinium and vilanterol inhalation, the pharmacokinetics was 
best described by a two-compartment model with first-order 
absorption. Again there was no apparent pharmacokinetic 
interaction when umeclidinium and vilanterol were coad-
ministered in patients with COPD. Age, bodyweight, and 
creatinine clearance did not significantly affect systemic 
exposure to either drug after inhalation.58 After inhalation 
of 125 µg umeclidinium and 25 µg vilanterol, the plasma 
concentration-time curves for umeclidinium and vilanterol 
were not significantly different between subjects with moder-
ate hepatic impairment and healthy volunteers.60
In exploring potential cardiac effects, healthy nonsmok-
ers received inhalers of UMEC 500 µg/VI 100 µg, UMEC 
125 µg/VI 25 µg, UMEC 500 µg, or placebo for 10 days.61 
Following the 10-day treatment, no clinically significant 
differences in QTc intervals were observed between those 
who inhaled UMEC 500 µg/VI 100 µg, those who inhaled 
UMEC 125 µg/VI 25 µg, and those who took the placebo. 
The supratherapeutic dose of 500 µg of umeclidinium 
with the supratherapeutic dose of 100 µg of vilanterol 
by inhalation increased the QTc interval by 4.2–8.2 msec 
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from 5 to 30 minutes after dosing.61 These changes were 
the same magnitude as the QTc interval changes seen with 
oral moxifloxacin (4.8–9.7 msec) 30 minutes to 12 hours 
after dosing.
Because these agents are very poorly absorbed, they are well 
tolerated. Antimuscarinic inhaled compounds have been associ-
ated with dry mouth, constipation, dyspepsia, gastroesophageal 
reflux, urinary retention, pupillary dilation, blurred vision, para-
doxical bronchoconstriction, and worsening of glaucoma.62 The 
adverse effects of LABA agents include palpitations, increased 
heart rates, supraventricular tachycardias, ectopy, nervousness, 
tremor, anxiety, hypokalemia, glycogenolysis, hyperglycemia, 
and paradoxical bronchoconstriction.62 Drug-related adverse 
events reported with inhaled umeclidinium/vilanterol in clini-
cal trials occurred at the rate of 1% and included headaches, 
nasopharyngitis, upper respiratory tract infections, dry mouth, 
dyspnea, and cough.53,55 
Conclusion
Medication adherence is not optimal in patients with chronic 
diseases, such as COPD. Many factors contribute to this poor 
medication adherence. Medication dosing frequency is one 
of the variables that contributes to poor medication adher-
ence in chronic diseases. Once-daily inhalers and particularly 
combination once-daily inhalers have been shown to improve 
medication adherence in COPD and are becoming more widely 
available as new products emerge on the market. The once-
daily combination umeclidinium (LAMA)/vilanterol (LABA) 
inhaler meets the criteria for the treatment of COPD and has 
favorable efficacy and favorable adverse effects profiles. 
Because the specific data for the UMEC/VI combined inhaler 
are limited, improved adherence has not been studied, but this 
inhaler should theoretically improve medication compliance in 
COPD. Other once-daily LAMA/LABA combination inhalers 
are available, are under clinical trials, and are likely soon to be 
on the USA market. These once-daily combination inhalers 
will likely become standard maintenance therapy for patients 
with moderate-to-severe COPD. 
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